x
CME-Tagline

Live Q&A: Unlocking the Value of Biosimilar Therapies in IBD

CMEO Webcast

Premiere Date: Thursday, March 11, 2021

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Friday, March 11, 2022

Faculty


Miguel Regueiro, MD, AGAF, FACG, FACP Miguel Regueiro, MD, AGAF, FACG, FACP 
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor, Department of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, OH

Statement of Need

Over the years, biologic agents have proven their importance in the management of chronic autoimmune diseases including inflammatory bowel disease (IBD). Biosimilars are molecules highly similar to approved biologic medicines that have been developed to mitigate the high costs of biologics. Despite the fact that these therapies are tested to ensure non-inferiority to originator products, questions about appropriate use of biosimilars in IBD remain among clinicians and patients alike.

This live question-and-answer session is your opportunity to ask questions based on the CME Outfitters virtual symposium, where expert faculty focused on identifying key terminology related to biosimilar products, assessing evidence regarding the efficacy and safety of biosimilars in IBD, and improving patient-provider communication patterns on the topic of biosimilars. To view the full activity ahead of this live Q&A, click here.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Identify the key terminology related to biosimilar products such as interchangeability, substitution, and switching.
  • Assess clinical trial and real-world evidence of efficacy and safety of biosimilars in IBD.
  • Improve patient-provider communication patterns regarding appropriate use of biosimilars.

The following learning objectives pertain only to those requesting CNE credit:

  • Identify the key terminology related to biosimilar products such as interchangeability, substitution, and switching.
  • Assess clinical trial and real-world evidence of efficacy and safety of biosimilars in IBD.
  • Explain how to improve patient-provider communication patterns regarding appropriate use of biosimilars.

Financial Support

This activity is supported by educational funding provided by Amgen

Target Audience

Gastroenterologists, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs). Universal Activity Number:
Live: 0376-0000-21-034-L01-P

Type: knowledge-based

Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Credit request forms and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately. This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Regueiro reports that he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on the advisory board or a consultant for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Olga Askinazi, PhD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

MMQ-111-031121-26